February 10, 2020 / 11:07 PM / in 2 months

BRIEF-Rexahn Pharmaceuticals Says On Feb 8, Co Entered Into Exclusive License Agreement With Zhejiang Haichang Biotechnology

Feb 10 (Reuters) - Rexahn Pharmaceuticals Inc:

* REXAHN PHARMACEUTICALS - ON FEB 8, CO ENTERED INTO EXCLUSIVE LICENSE AGREEMENT WITH ZHEJIANG HAICHANG BIOTECHNOLOGY

* REXAHN - HAICHANG WILL PAY CO DEVELOPMENT MILESTONE PAYMENTS OF UP TO $63 MILLION WITH RESPECT TO RX-0201 & RX-0301, UP TO $33 MILLION WITH RESPECT TO RX-0047

* REXAHN -CO GRANTED HAICHANG EXCLUSIVE SUBLICENSABLE WORLDWIDE LICENSE TO RESEARCH, DEVELOP, COMMERCIALIZE PRODUCTS COMPRISING RX-0201,RX-0301, RX-0047 Source text: (bit.ly/2vo1A88) Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below